Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab

Figure 1

Swimmer plot illustrating duration of IPI administration, date of complete remission (CR), date of stable disease (SD), time of baseline assessment and follow-up, and irAE of special interest. For 2 survivors, no assessment was available at one-year follow-up: one died (†) and one had recurrence of metastatic melanoma ().